Drug Trial Radar · NCT04766307
A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
Last checked: Nov 19, 2026Latest source record: Feb 23, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,100
Planned (sponsor's estimate)
Start
Jul 20, 2016
Primary completion
Dec 31, 2021
Study completion Dec 31, 2021
Sponsor
- Lead sponsor
- Beijing Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 23, 2021
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.
Conditions
- Tuberculosis, Pulmonary
Interventions
Interleukin-2Drug
Interleukin 2 (IL-2) is a pleiotropic cytokine that is produced after antigen activation and plays crucial roles in the immune response. IL-2 secreted by activated T cells is central to the development of an immune response to infection, promoting the differentiation and proliferation of lymphoid cells. This hydrophobic molecule and the various cytokines that it elicits regulates the behavior of T and B lymphocytes, monocytes/macrophages, natural killer (NK) cells, and neutrophils. IL-2 therapy regimens are expected to limit mycobacterial replication. Early clinical trials with IL-2 demonstrated that IL-2 immunotherapy may be useful in controlling infectious disease.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary study endpoint was the proportion of subjects who had converted their sputum cultures to negative at the end of treatment.Time frame: two-month course intensive phase treatment, followed by a four-month consolidation phase treatment.Some TB patients with cavity should receive 9 total months (7 months of continuation therapy after the initial 2-month intensive phase).
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
the Second hospital of Fuyang
Fuyang, Anhui, China · Recruiting
Fuzhou Chest Hospital
Fuzhou, Fujian, China · Recruiting
Shenzhen third people's Hospital
Shenzhen, Guangzhou, China · Recruiting
Guiyang Public Health Treatment Center
Guiyang, Guizhou, China · Recruiting
The Infectious Hospital of Handan
Handan, Hebei, China · Recruiting
Hebei Chest Hospital
Shijiazhuang, Hebei, China · Recruiting
Jiamusi Insititute For Tuberculosis Control
Jiamusi, Heilongjiang, China · Recruiting
The Infectious Hospital of mudanjiang
Mudanjiang, Heilongjiang, China · Recruiting
Zhengzhou Sixth People's Hospital
Zhengzhou, Henan, China · Recruiting
the central hospital of Changsha
Changsha, Hunan, China · Recruiting
the people's hospital of Jiangsu province
Nanjing, Jiangsu, China · Recruiting
Jiangxi Chest Hospital
Nanchang, Jiangxi, China · Recruiting
Dalian Tuberculosis Hospital
Dalian, Liaoning, China · Recruiting
Qingdao Chest Hospital
Qingdao, Shandong, China · Recruiting
Taiyuan Fourth People's Hospital
Taiyuan, Shanxi, China · Recruiting
Xian Chest Hospital
Xi’an, Shanxi, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.